This is a working overview of IGF-1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Carol Beattie is appointed chief executive of the Scottish National Party after taking on the post in an acting role following the resignation of her predecessor, Murray Foote. 11 March – The Metropolitan Police launch an investigation into Rupert Lowe over allegations of making "verbal threats". The Democracy and Boundary Commission has decided that all Senedd seats will have Welsh language only names from 2026. Reform UK gains its first representative on Falkirk Council following the defection of ex-Conservative turned Independent councillor Claire Mackie-Brown. 12 March – Keir Starmer says the UK will "keep all options on the table" regarding Donald Trump's steel and aluminium tariffs. All 404 Labour MPs are summoned to Downing Street for a briefing on the spring statement. Former First Minister of Scotland, Nicola Sturgeon, announces she will stand down from the Scottish Parliament at the 2026 election. Health Secretary Wes Streeting calls for his former assistant Sam Gould to resign from Redbridge London Borough Council after he admitted to indecent exposure. The requirement for a High Court judge to approve applications is dropped by the bill committee of the Terminally Ill Adults (End of Life) Bill. South Kesteven councillor Rosemary Trollope-Bellew leaves Reform UK just 11 days after joining. 13 March – Keir Starmer announces that NHS England will be abolished in order to "cut bureaucracy". First Minister of Scotland John Swinney holds talks with Eric Trump, the son of US President Donald Trump, at Bute House.
A combination of cilofexor/firsocostat was studied in people with bridging fibrosis and cirrhosis. It was observed to have led to improvements in NASH activity with a potential antifibrotic effect. Lanifibranor is also shown to prevent worsening fibrosis.
== Research == Ben-Tal's research is in computational structural biology, with an emphasis on developing computational methods to study protein structure, function, motion, and evolution. His laboratory investigates molecular systems for which computational approaches can provide information that is difficult to obtain experimentally. His research has included computational studies of membrane proteins and transporters, including the human copper transporter 1, the ATP7B copper-transporting ATPase, and sodium/proton exchangers. His group has also developed methods for predicting the structures and motions of membrane proteins and has applied computational approaches to questions in protein evolution and drug discovery.
Sources: en.wikipedia.org
Obesity increases the risk of many physical and mental conditions. These comorbidities are most commonly shown in metabolic syndrome, a combination of medical disorders which includes: diabetes mellitus type 2, high blood pressure, high blood cholesterol, and high triglyceride levels. The CDC has found that obesity is the single strongest risk factor for severe COVID-19 illness. Complications may be either directly caused by obesity or indirectly related through mechanisms sharing a common cause such as a poor diet or a sedentary lifestyle. The strength of the link between obesity and specific conditions varies. One of the strongest is the link with type 2 diabetes. Excess body fat underlies 64% of cases of diabetes in men and 77% of cases in women. Health consequences fall into two broad categories: those attributable to the effects of increased fat mass (such as osteoarthritis, obstructive sleep apnea, social stigmatization) and those due to the increased number of fat cells (diabetes, cancer, cardiovascular disease, non-alcoholic fatty liver disease). Increases in body fat alter the body's response to insulin, potentially leading to insulin resistance. Increased fat also creates a proinflammatory state, and a prothrombotic state.
== Organization == The Brigade's origins trace back to July 1941, when a "Fighter Battalion" (Destruction Battalion) led by I.T Gustev was established in the Mekhovsky District. By July 18th, this unit was reorganized into the Mekhovsky Partisan Detachment under the command of K.F Volkov. Following a winter of skirmishes and internal restructuring, the detachment was expanded to a brigade on May 7th, 1942, into the 2nd Belarusian Partisan Brigade. By January 1943, the brigade had grown to include 9 detachments. These were given honorary names of Soviet military and revolutionary figures, such as Suvorov, Chapayev , and Stalin.
=== Terminal transferases === Terminal transferases are transferases that can be used to label DNA or to produce plasmid vectors. It accomplishes both of these tasks by adding deoxynucleotides in the form of a template to the downstream end or 3' end of an existing DNA molecule. Terminal transferase is one of the few DNA polymerases that can function without an RNA primer.
The struggle continued until 10:03:11 a.m., when the aircraft crashed into a field in Stonycreek Township, near Shanksville, Pennsylvania, following a final roll onto its back, failing to reach the hijackers' intended target in Washington, D.C. The plane was about twenty minutes away from reaching D.C. at the time of the crash, and its target is believed to have been either the Capitol Building or the White House. Some passengers and crew who called from the aircraft using the cabin air phone service and mobile phones provided details: several hijackers were aboard each plane; they used mace, tear gas, or pepper spray to overcome attendants; and some people aboard had been stabbed. Reports indicated hijackers stabbed and killed pilots, flight attendants, and one or more passengers. According to the 9/11 Commission's final report, the hijackers had recently purchased multi-function hand tools and assorted Leatherman-type utility knives with locking blades, which were not forbidden to passengers at the time, but these were not found among the possessions left behind by the hijackers. A flight attendant on Flight 11, a passenger on Flight 175, and passengers on Flight 93 said the hijackers had bombs, but one of the passengers said he thought the bombs were fake. The FBI found no traces of explosives at the crash sites, and the 9/11 Commission concluded that the bombs were probably fake.
Sources: en.wikipedia.org
== History == 2000: Four scientists from what was then the Agricultural University of Norway (NLH), now the Norwegian University of Life Sciences (UMB) had the idea of replacing traditional date-stamping with something that can give a more correct indication of remaining shelf life for temperature sensitive products, such as food and pharmaceuticals. 2001: The fundamental principles for a shelf-life indicator were verified in the laboratory. The company TimeTemp AS, now Keep-it Technologies, was founded in 2001 to develop the technology into a commercial product. 2003: TimeTemp comes in second place in DNB’s national innovation competition. 2003-2007: The technology is tested and developed in the university's laboratories, and a working laboratory prototype is created. Keep-it Technologies is granted a patent in a number of different countries, including the US, Canada, Australia and New Zealand. 2007-2009: With support from the Research Council of Norway, Keep-it Technologies initiates an R&D project to develop the technology from laboratory prototype to an industrial prototype, and test it on real products through a professional cold chain. 2010-2011: The company raises new investment capital and initiates an IFU project that develops the first consumer version of the indicator. The indicator is tested on the first products in the Norwegian grocery market. 2012: Keep-it indicator is commercialized in Norway with the Norwegian retailer, Rema 1000. 2018: Keep-it has indicators on 30 different fresh products at Rema 1000, Kolonial.no and Oslo University Hospital.
=== Non-refrigerated fresh tempeh === Tempeh can be sold and consumed fresh within 48 hours once removed from its incubator. It is commonly transported to the market in its incubation container (e.g. polyethylene bag, banana leaf wrapper, etc.) and placed in the shade. In areas with warmer climates, tempeh can be kept at room temperature for one to three days before it becomes overripe. In locations with more temperate temperatures, it can keep for one to four days but will usually need to be refrigerated to prevent spoilage.
The East Prussian plebiscite (German: Volksabstimmung in Ostpreußen), also known as the Allenstein and Marienwerder plebiscite or Warmia, Masuria and Powiśle plebiscite (Polish: Plebiscyt na Warmii, Mazurach i Powiślu), was a plebiscite for the self-determination of the regions of southern Warmia (Ermland), Masuria (Mazury, Masuren) and Powiśle, which had been in parts of the East Prussian Government Region of Allenstein and of the West Prussian Government Region of Marienwerder in accordance with Articles 94 to 97 of the Treaty of Versailles. Prepared in early 1920, the plebiscite took place on 11 July 1920 and was conducted by German authorities under Inter-Allied control. The plebiscite reported that most voters had selected East Prussia over Poland (over 97% in the Allenstein Plebiscite Area and 92% in the Marienwerder Plebiscite Area). As a result, most of the territories in question remained in the Free State of Prussia and therefore in Germany.
rough endoplasmic reticulum (RER) A type of membrane in the endoplasmic reticulum with numerous ribosomes conspicuously attached to its surface, in contrast to the "smooth" endoplasmic reticulum which lacks ribosomes. The rough ER serves as the site of protein synthesis for the majority of the cell's secreted and transmembrane proteins, as well as the site of synthesis of membrane lipids. It may be continuous with the smooth ER or exist separately.
Seeded second at the Italian Open, he reached the semifinals defeating Cristian Garín in the quarterfinals. In the semifinals, he faced fourth seed, Stefanos Tsitsipas, again for the third consecutive time at this Masters level in the clay court season. He lost his semifinal match to Tsitsipas in three sets. Seeded third at the French Open, Zverev matched his semifinal result from the previous year, defeating sixth seed, Carlos Alcaraz, in the quarterfinals in what was his first top-10 victory at a major after 12 attempts. In his semifinal match against fifth seed, former world No. 1, and 13 time Roland Garros champion, Rafael Nadal, he retired 3 hours and 13 minutes into the match after rolling his right ankle and tearing all three lateral ligaments. He was rolled off the court in a wheelchair. Zverev informed that the injury would cause him to miss the 2022 Wimbledon Championships and on 8 June 2022 underwent surgery to repair the torn ligaments in his ankle. Despite his exit at Roland Garros, he reached a career-high ranking of world No. 2 on 13 June 2022. In September, he was due to return for the Davis Cup play but suffered a new injury, a bone edema, and withdrew from competition for the rest of the season. Zverev ended the year ranked 12, his lowest in five years, when he debuted in the top 10 and remained a fixture there.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.